 |
Interferon alfa-2a (recombinant) |
|---|---|
| Trade Name | Roferon-A |
| Orphan Indication | For the concomitant administration with Teceleukin for the treatment of metastatic renal cell carcinoma |
| USA Market Approval | USA |
| USA Designation Date | 1990-05-02 00:00:00 |
| Sponsor | Hoffmann-La Roche, Inc.;340 Kingsland Street;Nutley, New Jersey, 07119 |
